View Past PerformanceBiomea Fusion 대차대조표 건전성재무 건전성 기준 점검 4/6Biomea Fusion 의 총 주주 지분은 $29.6M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $58.6M 및 $29.0M 입니다.핵심 정보0%부채/자본 비율US$0부채이자보상배율n/a현금US$55.81m자본US$29.55m총부채US$29.02m총자산US$58.57m최근 재무 건전성 업데이트Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?Aug 17Biomea Fusion, Inc. Auditor Raises 'Going Concern' DoubtApr 02We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn RateSep 30We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth CarefullyJun 10We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business GrowthFeb 22Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?Nov 07모든 업데이트 보기Recent updatesBiomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentApr 29Biomea Fusion, Inc., Annual General Meeting, Jun 10, 2026Apr 28Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesMar 31New major risk - Financial position Mar 26Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For DiabetesMar 14Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular DiseaseDec 05Co-Founder recently bought US$55k worth of stock Dec 05Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025Nov 06Price target decreased by 10% to US$7.17 Nov 05Biomea Fusion, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2025Nov 05Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor AgonistOct 27Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient PopulationsOct 07+ 1 more updateBiomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines Oct 07Biomea Fusion, Inc. has filed a Follow-on Equity Offering.Oct 07Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal ModelSep 16Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?Aug 17Price target decreased by 27% to US$8.29 Aug 08Biomea Fusion, Inc. Announces Board ChangesJul 24Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 IndexJun 30+ 10 more updatesBiomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)Jun 24New major risk - Shareholder dilution Jun 18Biomea Fusion, Inc. has filed a Follow-on Equity Offering.Jun 18+ 1 more updateBiomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025Jun 13New major risk - Share price stability Jun 03Price target decreased by 14% to US$20.00 Jun 03Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute LeukemiaMay 15Price target decreased by 13% to US$20.50 May 06Biomea Fusion, Inc., Annual General Meeting, Jun 11, 2025Apr 22Biomea Fusion, Inc. Auditor Raises 'Going Concern' DoubtApr 02Biomea Fusion, Inc. Announces Chief Executive Officer ChangesMar 26Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last DoseMar 25New major risk - Revenue and earnings growth Mar 24New minor risk - Market cap size Mar 04Price target decreased by 34% to US$28.11 Jan 13Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination StudyJan 07Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDec 18Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaDec 10Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes ManagementNov 21Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateNov 02High number of new and inexperienced directors Nov 01Independent Director recently bought US$101k worth of stock Oct 02Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes ExpertsOct 01+ 3 more updatesWe're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn RateSep 30Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes TrialsSep 27New major risk - Financial position Jul 01High number of new and inexperienced directors Jun 17CFO & Principal Accounting Officer recently bought US$55k worth of stock Jun 13We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth CarefullyJun 10Price target decreased by 17% to US$41.00 Jun 09Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical HoldJun 08New major risk - Share price stability Jun 08Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesMay 31Price target increased by 10% to US$54.43 May 05Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024Apr 28Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)Apr 03Price target decreased by 9.2% to US$49.38 Apr 02Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionMar 06We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business GrowthFeb 22Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219Jan 09New major risk - Revenue and earnings growth Dec 31Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, DiabetesDec 08Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 DiabetesDec 05New minor risk - Share price stability Nov 30Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)Nov 09Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?Nov 07New major risk - Revenue and earnings growth Nov 05Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023Nov 04Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)Oct 18Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii StudySep 29Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical OfficerSep 01New major risk - Revenue and earnings growth Aug 11New major risk - Revenue and earnings growth Jul 29Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent MutationsJul 25We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth CarefullyJul 12Price target increased by 17% to US$48.63 Jun 26Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific SessionsJun 24Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaMay 05Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn SituationMar 29Price target increased by 24% to US$27.50 Mar 29Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid TumorsJan 18Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219Jan 05Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 DiabetesDec 16Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to DateDec 13재무 상태 분석단기부채: BMEA 의 단기 자산 ( $58.1M )이 단기 부채( $11.1M ).장기 부채: BMEA의 단기 자산($58.1M)이 장기 부채($17.9M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: BMEA 부채가 없습니다.부채 감소: BMEA는 5년 전 부채 대비 자본 비율이 0.06%였으나 현재 부채가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: BMEA 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 30 %의 역사적 비율로 계속 감소할 경우 BMEA 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/30 09:46종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biomea Fusion, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Naureen QuibriaCapital One Securities, Inc.Yigal NochomovitzCitigroup IncJason KolbertD. Boral Capital LLC.11명의 분석가 더 보기
Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentApr 29
Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesMar 31
Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For DiabetesMar 14
Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular DiseaseDec 05
Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025Nov 06
Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor AgonistOct 27
Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient PopulationsOct 07+ 1 more update
Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal ModelSep 16
Biomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)Jun 24
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025Jun 13
Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute LeukemiaMay 15
Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last DoseMar 25
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDec 18
Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaDec 10
Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes ManagementNov 21
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateNov 02
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes ExpertsOct 01+ 3 more updates
Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes TrialsSep 27
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesMay 31
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)Apr 03
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionMar 06
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219Jan 09
Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, DiabetesDec 08
Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 DiabetesDec 05
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)Nov 09
Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)Oct 18
Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii StudySep 29
Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent MutationsJul 25
Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific SessionsJun 24
Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaMay 05
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid TumorsJan 18
Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219Jan 05
Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 DiabetesDec 16
Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to DateDec 13
